Antitumor Metallothiosemicarbazonates: Structure and Antitumor Activity of Palladium Complex of Phenanthrenequinone Thiosemicarbazone
The crystal structure of the potential antitumor metal compound, viz. chloro, mono(phenanthrenequinone thiosemicarbazonato) palladium(II) dimethyl formamide solvate, is reported. The central palladium(II) atom is in a square planar environment provided by the tridentate, monoanionic thiosemicarbazone ligand and the ancillary chloride ion. The compound exhibited remarkable activity against drug-sensitive and drug-resistant breast cancer cell lines and was relatively nontoxic toward the normal mammary epithelial cells. The drug-induced killing effect against breast cancer cell lines was predominantly mediated via apoptosis, a physiologic form of cell death.
S. B. Padhyé et al., "Antitumor Metallothiosemicarbazonates: Structure and Antitumor Activity of Palladium Complex of Phenanthrenequinone Thiosemicarbazone," Inorganic Chemistry, vol. 44, no. 5, pp. 1154-1156, American Chemical Society (ACS), Mar 2005.
The definitive version is available at https://doi.org/10.1021/ic048214v
Keywords and Phrases
antineoplastic agent; chloride ion; chloro (phenanthrenequinone thiosemicarbazone) palladium dimethyl formamide solvate; metallothiosemicarbazonate; mono (phenanthrenequinone thiosemicarbazone) palladium dimethyl formamide solvate; palladium complex; thiosemicarbazone derivative; unclassified drug; viz (phenanthrenequinone thiosemicarbazone); Breast cancer; Copper dimer; Phenanthroline adduct; Sparfloxacin; X-ray crystal structurepalladium dimethyl formamide solvate; antineoplastic activity; apoptosis; article; breast cancer; cancer cell; cell death; cell line; crystal structure; drug resistance; drug sensitivity; structure analysis; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Molecular Structure; Phenanthrenes; Thiosemicarbazones
International Standard Serial Number (ISSN)
Article - Journal
© 2005 American Chemical Society (ACS), All rights reserved.
01 Mar 2005